Regeneron Announces Webcast Presentation of Results from Phase 2 Study of ARCALYST(R)...

Regeneron Announces Webcast Presentation of Results from Phase 2 Study of ARCALYST(R) (rilonacept) in Gout Patients Initiating Urate-Lowering Therapy

TARRYTOWN, N.Y.--(Business Wire)--
Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced
that Dr. Leonard S. Schleifer, President and Chief Executive Officer
of Regeneron, and other members of senior management will host a
webcast conference call commencing at 8:30 a.m. Eastern Time on
Wednesday, September 3, 2008. Dr. Schleifer will discuss the findings
of a Phase 2 study evaluating the efficacy and safety of ARCALYST(R)
(rilonacept) versus placebo in the prevention of gout flares induced
by the initiation of uric acid-lowering drug therapy that is used to
control gout. A separate press release announcing the study findings
will be issued by the Company prior to the conference call. The
interactive call can be accessed live through the Regeneron website at
www.regeneron.com on the Presentations page of the Investor Relations
section. The call, including the question and answer session, can also
be accessed by dialing:

-0-
*T
Domestic Dial-in Number: (866)314-5050
International Dial-in Number: (617)213-8051
Participant Passcode: 16355081
*T

For those unable to participate during the call, a replay will be
available from 10:30 a.m. Eastern Time on September 3, 2008 through
October 3, 2008. The call can be accessed by dialing:

-0-
*T
Domestic Dial-in Number: (888)286-8010
International Dial-in Number: (617)801-6888
Participant Passcode: 58761816
*T

The replay will be available over the Internet and can be accessed
by visiting the Regeneron website at www.regeneron.com on the
Presentations page of the Investor Relations section.

Important Information About ARCALYST

ARCALYST is indicated for the treatment of Cryopyrin-Associated
Periodic Syndromes (CAPS), including Familial Cold Auto-inflammatory
Syndrome (FCAS) and Muckle-Wells Syndrome (MWS) in adults and children
12 and older. IL-1 blockade may interfere with immune response to
infections. Serious, life-threatening infections have been reported in
patients taking ARCALYST. ARCALYST should be discontinued if a patient
develops a serious infection. Taking ARCALYST with tumor necrosis
factor inhibitors is not recommended because this may increase the
risk of serious infections. Treatment with ARCALYST should not be
initiated in patients with active or chronic infections. Patients
should not receive a live vaccine while taking ARCALYST. It is
recommended that patients receive all recommended vaccinations prior
to initiation of treatment with ARCALYST. Patients should be monitored
for changes in their lipid profiles and provided with medical
treatment if warranted. Hypersensitivity reactions associated with
ARCALYST(R) (rilonacept) administration have been rare. Please see the
full Prescribing Information for ARCALYST, available online at
www.regeneron.com/ARCALYST-fpi.pdf.

About Regeneron Pharmaceuticals, Inc.

Regeneron is a fully integrated biopharmaceutical company that
discovers, develops, and commercializes medicines for the treatment of
serious medical conditions. In addition to ARCALYST(R) (rilonacept)
Injection for Subcutaneous Use, its first commercialized product,
Regeneron has therapeutic candidates in clinical trials for the
potential treatment of cancer, eye diseases, and inflammatory
diseases, and has preclinical programs in other diseases and
disorders. Additional information about Regeneron and recent news
releases are available on Regeneron's web site at www.regeneron.com.

Forward Looking Statement

This news release discusses historical information and includes
forward-looking statements about Regeneron and its products,
development programs, finances, and business, all of which involve a
number of risks and uncertainties, such as risks associated with
preclinical and clinical development of Regeneron's drug candidates,
determinations by regulatory and administrative governmental
authorities which may delay or restrict Regeneron's ability to
continue to develop or commercialize its product and drug candidates,
competing drugs that are superior to Regeneron's product and drug
candidates, uncertainty of market acceptance of Regeneron's product
and drug candidates, unanticipated expenses, the availability and cost
of capital, the costs of developing, producing, and selling products,
the potential for any collaboration agreement, including Regeneron's
agreements with the sanofi-aventis Group and Bayer HealthCare, to be
canceled or to terminate without any product success, risks associated
with third party intellectual property, and other material risks. A
more complete description of these and other material risks can be
found in Regeneron's filings with the United States Securities and
Exchange Commission (SEC), including its Form 10-K for the year ended
December 31, 2007 and Form 10-Q for the quarter ending June 30, 2008.
Regeneron does not undertake any obligation to update publicly any
forward-looking statement, whether as a result of new information,
future events, or otherwise unless required by law.

Regeneron Pharmaceuticals, Inc.
Investor Relations
914-345-7640
invest@regeneron.com
or
Corporate Communications
Laura Lindsay, 914-345-7800
laura.lindsay@regeneron.com
or
Media Relations
Lauren Tortorete, 212-845-5609
ltortorete@biosector2.com

Copyright Business Wire 2008